-5%
Monotherapy & Combination Therapy: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.
Safety and efficacy have not been established in patients with a history of pancreatitis. It is unknown whether such patients are at higher risk of developing pancreatitis with Sitap.
Sitagliptin is a DPP-4 inhibitor that prolongs the activity of incretin hormones (GLP-1 and GIP), which play a role in glucose homeostasis.
Increases insulin synthesis and release from pancreatic β-cells in a glucose-dependent manner.
Reduces glucagon secretion from pancreatic α-cells, lowering hepatic glucose production.
Highly selective for DPP-4, with minimal effect on DPP-8 or DPP-9.
Pediatric: Safety and efficacy not established (<18 years).
Geriatric: Use with caution due to potential renal impairment. Monitor renal function regularly.